Poland's competition watchdog UOKiK has handed pharmaceutical wholesaler Neuca its largest-ever fine — 499 million zlotys ($131 million) — for its role in a drug pricing cartel that ran for more than a decade. Three other wholesalers were also penalized, bringing the total fines to 905 million zlotys. Together, the three largest groups controlled over 70% of Poland's wholesale drug market.

The cartel operated by exploiting pharmacy loyalty programmes, which gave wholesalers access to purchasing data. This allowed them to monitor rivals' pricing and terms for individual pharmacies and adjust their own offers accordingly. Polska Grupa Farmaceutyczna escaped financial penalties by cooperating with investigators under UOKiK's leniency program and providing key evidence. The decision is not yet final, and companies may appeal to court.

By the Numbers:

• 499M zlotys (~$131M): Fine levied against Neuca alone
• 905M zlotys: Total fines across all four wholesalers
• 10+ years: Duration of the pricing cartel
• 70%+: Market share controlled by the three largest wholesaler groups
• 13.6%: Single-day share price drop for Neuca — its worst ever

Why it matters: Anti-competitive practices in pharmaceutical distribution can distort drug pricing at scale, ultimately affecting what pharmacies — and patients — pay. This ruling sends a strong signal to the broader pharma supply chain about the consequences of market manipulation.